热门资讯> 正文
XTL宣布收到纳斯达克通知
2026-01-24 05:25
- XTL Biopharmaceuticals (NASDAQ:XTLB) said on Friday it received a notice from Nasdaq on January 20, 2026, that the company is not in compliance with the continued listing requirements to maintain the minimum $2.5M in stockholders’ equity.
- Nasdaq said its determination was based on the company’s Dec. 30, 2025, Form 6-K showing a $47,000 stockholders’ equity deficit and its failure to meet alternative listing standards as of Jan. 20, 2026.
- The company said it is evaluating options to regain compliance and intends to do so within Nasdaq’s required timeframe.
More on XTL Biopharmaceuticals
- Seeking Alpha’s Quant Rating on XTL Biopharmaceuticals
- Financial information for XTL Biopharmaceuticals
推荐文章
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
